keyword
MENU ▼
Read by QxMD icon Read
search

Rosuvastatin

keyword
https://www.readbyqxmd.com/read/28729172/ascorbic-acid-supplementation-partially-prevents-the-delayed-reproductive-development-in-juvenile-male-rats-exposed-to-rosuvastatin-since-prepuberty
#1
Gabriel Adan Araújo Leite, Thamiris Moreira Figueiredo, Marciana Sanabria, Ana Flávia Mota Gonçalves Dias, Patrícia Villela E Silva, Airton da Cunha Martins, Fernando Barbosa, Wilma De Grava Kempinas
Dyslipidemias are occurring earlier in the population due to the increase of obesity and bad eating habits. Rosuvastatin inhibits the enzyme HMG-CoA reductase, decreasing total cholesterol. Ascorbic acid is an important antioxidant compound for male reproductive system. This study aimed to evaluate whether ascorbic acid supplementation may prevent the reproductive damage provoked by rosuvastatin administration at prepuberty. Male pups were distributed into six experimental groups that received saline solution 0...
July 17, 2017: Reproductive Toxicology
https://www.readbyqxmd.com/read/28725138/comparative-assessment-of-saliva-and-plasma-for-drug-bioavailability-and-bioequivalence-studies-in-humans
#2
Nasir M Idkaidek
Aims: To study the pharmacokinetics of selected drugs in plasma and saliva matrixes in healthy human volunteers, and to suggest using non-invasive saliva sampling instead of plasma as a surrogate in bioavailability and bioequivalence (BA/BE) studies. Methods: Four different pilot BA/BE studies were done in 12-18 healthy humans. Saliva and plasma samples were collected for 3-5 half life values of metformin, tolterodine, rosuvastatin, and paracetamol after oral dosing. Saliva and plasma samples were assayed using LC-MSMS, and then pharmacokinetic parameters were calculated by non-compartmental analysis using Kinetica program...
July 2017: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/28721135/a-comprehensive-guidelines-based-approach-reduces-cardiovascular-risk-in-everyday-practice-the-varo-study
#3
Tomáš Štulc, Věra Lánská, Michaela Šnejdrlová, Michal Vrablík, Martina Prusíková, Richard Češka
INTRODUCTION: The aim of study was to investigate the possibility of cardiovascular risk improvement through systematic identification of high-risk individuals and treatment in accordance with current guidelines using modern therapy in daily clinical practice. MATERIAL AND METHODS: Two hundred and sixty-three physicians participated in the study. The physicians were asked to screen for cardiovascular risk factors in patients presenting with unrelated problems and to re-evaluate the attainment of treatment goals in those with already known risk factors...
June 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28711864/high-intensity-statin-therapy-is-associated-with-improved-survival-in-patients-with-peripheral-artery-disease
#4
Raymond Foley, Gagan D Singh, Damianos G Kokkinidis, Ho-Hin K Choy, Thai Pham, Ezra A Amsterdam, John C Rutledge, Stephen W Waldo, Ehrin J Armstrong, John R Laird
BACKGROUND: The relative benefit of higher statin dosing in patients with peripheral artery disease has not been reported previously. We compared the effectiveness of low- or moderate-intensity (LMI) versus high-intensity (HI) statin dose on clinical outcomes in patients with peripheral artery disease. METHODS AND RESULTS: We reviewed patients with symptomatic peripheral artery disease who underwent peripheral angiography and/or endovascular intervention from 2006 to 2013 who were not taking other lipid-lowering medications...
July 15, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28706385/acylation-stimulating-protein-is-a-surrogate-biomarker-for-acute-myocardial-infarction-role-of-statins
#5
Hayder M Al-Kuraishy, Ali I Al-Gareeb
BACKGROUND: Acylation-stimulating protein (ASP) is an adipokine synthesized within adipocytes environment due to adipocyte differentiation. AIM: The aim of this study was to assess changes in ASP levels in patients with acute myocardial infarction (MI) and to correlate these variations with disease variables. SUBJECTS AND METHODS: A total number of 111 patients previously and currently treated with rosuvastatin or atorvastatin presented with acute MI in a Coronary Care Unit, were divided into three groups, Group A: Thirty-nine patients treated with atorvastatin, Group B: Thirty patients treated with rosuvastatin, compared to 42 patients presented with MI not previously treated with statins were enrolled in this study...
July 2017: Journal of Laboratory Physicians
https://www.readbyqxmd.com/read/28697767/the-impact-of-the-time-of-drug-administration-on-the-effectiveness-of-combined-treatment-of-hypercholesterolemia-with-rosuvastatin-and-ezetimibe-roseze-study-protocol-for-a-randomized-controlled-trial
#6
Karolina Obońska, Michał Kasprzak, Joanna Sikora, Ewa Obońska, Krzysztof Racki, Natalia Goździkiewicz, Magdalena Krintus, Jacek Kubica
BACKGROUND: Hypercholesterolemia is one of the main risk factors for cardiovascular disease. The first line treatment for hypercholesterolemia is statin therapy. When the expected low-density lipoprotein cholesterol (LDL-C) concentration is not achieved, the pharmacotherapy may be extended by combining the statin with the cholesterol absorption inhibitor ezetimibe. METHODS/DESIGN: The study is designed as a randomized, open-label, single-center, crossover study evaluating the effectiveness of combined therapy with rosuvastatin and ezetimibe for hypercholesterolemia...
July 11, 2017: Trials
https://www.readbyqxmd.com/read/28685516/comparison-between-atorvastatin-and-rosuvastatin-in-renal-function-decline-among-patients-with-diabetes
#7
Eugene Han, Gyuri Kim, Ji Yeon Lee, Yong Ho Lee, Beom Seok Kim, Byung Wan Lee, Bong Soo Cha, Eun Seok Kang
BACKGROUND: Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes. METHODS: We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treated with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day)...
June 2017: Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28685495/effects-of-metformin-and-furosemide-on-rosuvastatin-pharmacokinetics-in-healthy-volunteers-implications-for-their-use-as-probe-drugs-in-a-transporter-cocktail
#8
Peter Stopfer, Thomas Giessmann, Kathrin Hohl, Ashish Sharma, Naoki Ishiguro, Mitchell E Taub, Arvid Jungnik, Dietmar Gansser, Thomas Ebner, Fabian Müller
BACKGROUND: In a recently described probe drug cocktail for clinically relevant drug transporters containing digoxin, furosemide, metformin and rosuvastatin, mutual interactions were essentially absent except for increases in the systemic exposure of rosuvastatin. To optimize the cocktail, we further examined the dose dependence of the effects of metformin and furosemide on rosuvastatin pharmacokinetics. METHODS: This was a randomized, open label, single center, six-treatment, six-period, six-sequence crossover trial...
July 6, 2017: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/28683645/substitution-of-nevirapine-or-raltegravir-for-protease-inhibitor-vs-rosuvastatin-treatment-for-the-management-of-dyslipidaemia-in-hiv-infected-patients-on-stable-antiretroviral-therapy-nevrast-study
#9
Leonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, Marco Borderi, Linda Bussini, Isabella Bon, Maria Carla Re, Pierluigi Viale
OBJECTIVES: An observational, prospective, cohort study was performed to compare efficacy and safety of a switch from ritonavir-boosted protease inhibitor (PI/r) to nevirapine or raltegravir with that of rosuvastatin addition to current antiretroviral therapy in HIV-infected patients with hyperlipidaemia. METHODS: All HIV-infected patients receiving a stable PI/r-based antiretroviral regimen, with persistently suppressed viremia, naïve to non-nucleoside analogues and to integrase strand transfer inhibitors, with mixed hyperlipidaemia, and who underwent a switch from PI/r to nevirapine (Group A) or raltegravir (Group B) or who started rosuvastatin at 10 mg daily (group C) with unchanged antiretroviral regimen were enrolled into the study...
July 6, 2017: Infectious Diseases
https://www.readbyqxmd.com/read/28683192/evaluation-of-the-possible-nephroprotective-effects-of-vitamin-e-and-rosuvastatin-in-amikacin-induced-renal-injury-in-rats
#10
Ahmed Selim, Marwa M Khalaf, Amany M Gad, Ola M Abd El-Raouf
Amikacin (AMIK) is an aminoglycoside antibiotic that possesses considerable nephrotoxic adverse effects. This study examined the protective effects of vitamin E (VIT. E) or rosuvastatin (ROSU) against AMIK-induced nephrotoxicity. For this purpose, eight groups of rats were used. Two control groups received saline and vehicle, AMIK group (1.2 g/kg, i.p.), VIT. E group (1000 mg/kg; p.o.), ROSU group (10 mg/kg; p.o.), AMIK + VIT. E group, AMIK + ROSU group, and combination group. The results showed that AMIK significantly increased serum levels of urea and creatinine...
July 6, 2017: Journal of Biochemical and Molecular Toxicology
https://www.readbyqxmd.com/read/28682890/efficacy-of-short-term-moderate-or-high-dose-rosuvastatin-in-preventing-contrast-induced-nephropathy-a-meta-analysis-of-15-randomized-controlled-trials
#11
REVIEW
Min Liang, Shicheng Yang, Naikuan Fu
BACKGROUND: The prophylactic efficacy of statin pretreatment for the prevention of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) remains controversial. The aim of the study was to perform a meta-analysis of randomized controlled trials (RCTs) to assess the effectiveness of short-term moderate or high-dose rosuvastatin pretreatment in preventing CIN. METHODS: We included RCTs comparing short-term moderate or high-dose rosuvastatin treatment versus low-dose rosuvastatin treatment or placebo for preventing CIN...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28679524/relationship-between-serum-inflammatory-marker-levels-and-the-dynamic-changes-in-coronary-plaque-characteristics-after-statin-therapy
#12
RANDOMIZED CONTROLLED TRIAL
Osung Kwon, Soo-Jin Kang, Se Hun Kang, Pil Hyung Lee, Sung-Cheol Yun, Jung-Min Ahn, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Ki Hoon Han, Seong-Wook Park, Seung-Jung Park
BACKGROUND: The mechanism of statin for atheroma stabilization remains unclear. We aimed to assess the relationship between on-treatment changes in serum inflammatory biomarker levels and plaque composition in differed nonculprit coronary lesions. METHODS AND RESULTS: The changes in serum biochemical values, and intravascular ultrasound data were evaluated in 218 patients with virtual histology (VH)-intravascular ultrasound-defined fibroatheroma-containing segments after 12-month rosuvastatin treatment...
July 2017: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28676027/the-co-existence-of-nash-and-chronic-kidney-disease-boosts-cardiovascular-risk-are-there-any-common-therapeutic-options
#13
Marianna Papademetriou, Vasilios G Athyros, Eleni Geladari, Michael Doumas, Costas Tsioufis, Vasilios Papademetriou
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease. NAFLD may evolve to non-alcoholic steatohepatitis (NASH), which is causally related to cirrhosis and cardiovascular disease (CVD) mortality. There is no generally accepted effective treatment for NAFLD/NASH. Chronic kidney disease (CKD) is relatively common and might co-exist with NAFLD/NASH, aggravate one another, and increase CVD risk. Common therapies could improve outcome. Potent statins at high doses, such as atorvastatin and rosuvastatin, ameliorate NAFLD/NASH and reduce the mortality rates by half as compared with those on the same statins but without liver disease...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28673294/lipid-management-in-india-a-nationwide-cross-sectional-physician-survey
#14
Gurpreet S Wander, Uday M Jadhav, Amruta Chemburkar, Meena Lopez, Jaideep Gogtay
BACKGROUND: Current international guidelines on dyslipidemia are not concordant on various aspects of management. Also, there are no uniformly accepted Indian guidelines. We, therefore, performed a physician survey to understand lipid management practices in India. METHODS: An anonymous survey questionnaire was administered to gauge physicians' self-reported behavior regarding lipid management aspects. Results were expressed in terms of percentages based on the number of responses obtained...
July 3, 2017: Lipids in Health and Disease
https://www.readbyqxmd.com/read/28669329/effect-of-low-5-mg-vs-high-20-40-mg-rosuvastatin-dose-on-24h-arterial-stiffness-central-haemodynamics-and-non-alcoholic-fatty-liver-disease-in-patients-with-optimally-controlled-arterial-hypertension
#15
Eudoxia Mitsiou, Chrysoula Boutari, Vasilios Kotsis, Eleni Georgianou, Michael Doumas, Asterios Karagiannis, Vasilios G Athyros
OBJECTIVE: Arterial stiffness (AS) and non-alcoholic fatty liver diseases (NAFLD) are 2 related, prevalent, risk predictors of cardiovascular disease (CVD). We assessed the effect of low dose (5 mg/day) vs high dose (20-40 mg/day) rosuvastatin on aortic elasticity and central haemodynamics as well as on NAFLD in patients with arterial hypertension (AH). PATIENTS-METHODS: Forty patients with optimally controlled AH were randomised to 2 rosuvastatin doses and followed for 6 months...
June 30, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28665545/inhibition-of-mevalonate-pathway-prevents-ischemia-induced-cardiac-dysfunction-in-rats-via-rhoa-independent-signaling-pathway
#16
Ying Yang, Xiqing Rong, Xue Lv, Wenbing Jiang, Yuan Yang, Dongwu Lai, Shiming Xu, Guosheng Fu
AIM: We previously demonstrated that anoxia-mediated Ca(2+) handling dysfunction could be ameliorated through inhibition of mevalonate pathway via RhoA- and Ras-related mechanisms in H9c2 cells. In this study, we further explored whether inhibition of mevalonate pathway is associated with cardiac remodeling and dysfunction in ischemic cardiomyopathy, and discuss the possible role of Ras, Rac and RhoA in cardiac dysfunction. METHODS: We investigated the role of mevalonate pathway in cardiac remodeling and cardiomyocyte Ca(2+) handling proteins expression in a rat model of cardiac dysfunction due to myocardial infarction (MI)...
June 30, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28656677/author-s-response-to-letter-to-the-editor-on-physiologically-based-pharmacokinetic-predictions-of-intestinal-bcrp-mediated-effect-of-telmisartan-on-the-pharmacokinetics-of-rosuvastatin-in-humans
#17
https://www.readbyqxmd.com/read/28655408/autoimmune-hepatitis-immune-mediated-liver-injury-induced-by-rosuvastatin
#18
Mara Sánchez, Agustin Castiella, Eva Zapata, Leire Zubiaurre, Josu Pérez-Yeboles, Leire Mendibil, Arantxa Iribarren
No abstract text is available yet for this article.
June 24, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/28653144/explaining-ethnic-variability-of-transporter-substrate-pharmacokinetics-in-healthy-asian-and-caucasian-subjects-with-allele-frequencies-of-oatp1b1-and-bcrp-a-mechanistic-modeling-analysis
#19
Rui Li, Hugh A Barton
BACKGROUND: Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates...
June 26, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28641153/lipoprotein-a-and-coronary-atheroma-progression-rates-during-long-term-high-intensity-statin-therapy-insights-from-saturn
#20
Rishi Puri, Christie M Ballantyne, Ron C Hoogeveen, Mingyuan Shao, Philip Barter, Peter Libby, M John Chapman, Raimund Erbel, Benoit J Arsenault, Joel S Raichlen, Steven E Nissen, Stephen J Nicholls
BACKGROUND & AIMS: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL)-like particle that associates with major adverse cardiovascular events (MACE). We examined relationships between Lp(a) measurements and changes in coronary atheroma volume following long-term maximally-intensive statin therapy in coronary artery disease patients. METHODS: Study of coronary atheroma by intravascular ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) used serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months...
June 15, 2017: Atherosclerosis
keyword
keyword
6832
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"